Belite Bio (BLTE) news
Recent news
Perceptive Advisors exits drug, BLTE, EVMN, NMRA in 2Q: 13F
Perceptive Advisors LLC, a biotech-focused investment firm, disclosed its second-quarter 2026 portfolio changes in a recent 13F filing. The firm exited several positions, including drugmaker Belite Bio (BLTE), Evommune (EVMN), and Neumora Therapeutics (NMRA), as part of its strategic rebalancing…
AInvest Wire · Aug 14, 2026Belite Bio, Inc: H.C. Wainwright raises target price to $214 from $200
H.C. Wainwright has raised its price target for Belite Bio, Inc (NASDAQ:BLTE) to $214 from $200, while maintaining its Buy rating. The stock is currently trading at $161.08, close to its 52-week high, and has delivered a 170% return over the past year. The analyst consensus remains Strong Buy, with…
AInvest Wire · Aug 12, 2026Belite Bio - FDA sets PDUFA date of February 12, 2027 for Tinlarebant NDA
AInvest Wire · Aug 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.